Edaravone in Digestive Diseases - A Narrative Review
Haiyun Lei1, Mingchun Wang1, Ma Huang1
1Department of Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, People's Republic of China.
Drug Design, Development and Therapy
|June 18, 2025
Summary
Edaravone, a free radical scavenger, shows promise for treating digestive diseases by reducing oxidative stress and inflammation. Further research into its therapeutic potential could lead to new treatments for complex gastrointestinal disorders.
Area of Science:
- Gastroenterology and Hepatology
- Pharmacology
- Biomedical Research
Background:
- Digestive diseases present complex challenges with limited treatment options for many conditions.
- Existing therapies are insufficient for numerous gastrointestinal disorders, necessitating novel therapeutic agents.
- Edaravone, a neuroprotective agent, has a well-established safety profile and minimal adverse effects.
Purpose of the Study:
- To review the current understanding of Edaravone's therapeutic potential in digestive diseases.
- To explore Edaravone's mechanisms of action relevant to gastrointestinal pathophysiology.
- To highlight advances in Edaravone's application in digestive disease models and clinical settings.
Main Methods:
- Literature review of Edaravone's pharmacological properties.
- Analysis of studies investigating Edaravone in digestive disease models.
- Examination of clinical data on Edaravone's use in gastrointestinal conditions.
Main Results:
- Edaravone demonstrates antioxidant, anti-inflammatory, and tissue-repair properties relevant to digestive diseases.
- Preclinical and clinical evidence suggests Edaravone's efficacy in various digestive disease contexts.
- Edaravone's safety profile supports its consideration for gastrointestinal applications.
Conclusions:
- Edaravone is a promising therapeutic candidate for managing diverse digestive diseases.
- Its multifaceted mechanisms offer potential for improved treatment strategies and clinical outcomes.
- Further research is warranted to fully elucidate Edaravone's role in gastroenterology.
More Related Videos
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
205
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
205
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
222
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
222
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
709
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
709
01:26Peptic Ulcer Disease IV: Management
151
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
151
01:29Drugs for Treatment of Ulcerative Colitis in IBD
244
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
244
01:17Chronic Bowel Disorders: Introduction
544
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
544